This could be due to the fact that, among the anti-TNF class of drugs, infliximab is often preferred in ulcerative colitis patients as it has shown a better efficacy [49]; subsequently, the majority of patients undergoing adalimumab are affected by Crohn’s disease. Here, TNF is linked to ulcerative colitis.